Showing results (361-370 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 25, 2010
New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potentialMaria Teresa Conconi, Giovanni Marzaro, Adriano Guiotto, et al.
Investigational New Drugs|July 2, 2011
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancerJinah Park, Eunju Park, Sae-Won Han, et al.
Investigational New Drugs|October 17, 2007
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumorsElisabeth I Heath, Keith Bible, Robert E Martell, et al.
Investigational New Drugs|June 19, 2007
Naphthylnitrobutadienes as pharmacologically active molecules: evaluation of the in vivo antitumour activityGiovanni Petrillo, Carla Fenoglio, Emanuela Ognio, et al.
Investigational New Drugs|March 7, 2012
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomasAngela Ruban, Tamara Berkutzki, Itzik Cooper, et al.
Investigational New Drugs|December 6, 2011
First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumorsKazuhiro Araki, Koichi Kitagawa, Hirofumi Mukai, et al.
Investigational New Drugs|April 25, 2012
Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathwaysJin Sun Yoon, Young Woong Won, Seo Ju Kim, et al.
Investigational New Drugs|May 2, 2012
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancerDaniel Laheru, Preeti Shah, N V Rajeshkumar, et al.
Investigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.
Investigational New Drugs|February 22, 2012
Aurora kinase inhibitors: progress towards the clinicMadhu Kollareddy, Daniella Zheleva, Petr Dzubak, et al.
Pageof 372